Understanding brain penetrance of anticancer drugs
نویسندگان
چکیده
منابع مشابه
Understanding and improving platinum anticancer drugs--phenanthriplatin.
Approximately half of all patients who receive anticancer chemotherapy are treated with a platinum drug. Despite the widespread use of these drugs, the only cure that can be claimed is that of testicular cancer following cisplatin treatment. This article reviews some of our recent work on phenanthriplatin, a cisplatin derivative in which a chloride ion is replaced by phenanthridine, and on one ...
متن کاملChromatography of Anticancer Drugs
Chromatographic techniques have been developed and successfully applied for the analysis of a considerable of number of organic and inorganic compounds present at trace level in sometimes complicated accompanying matrices. The rapid development of new chromatographic instrumentation and separation strategies resulted in the increase of the number of chromatographic technologies with higher sepa...
متن کاملMechanisms of anticancer drugs
Introduction 34 Principles of chemotherapy 34 Principles of tumour biology 34 Classification of chemotherapeutic agents 37 Limitations of cytotoxic agents 40 Chemotherapy in head and neck cancer 40 Choice of chemotherapy in head and neck cancer 40 Chemotherapy strategies 40 Novel therapies for the future 41 Other novel treatments 44 Conclusion 44 Key points 45 Deficiencies in current knowledge ...
متن کاملNezw Drugs Anticancer chemotherapy
Though the selection and administration of cytotoxic drugs is usually restricted to specialist units, all doctors should be aware of both the available treatment and its associated problems. This review concerns new cytotoxic drugs and some new applications of current drugs. It is largely confined to drugs marketed in the United Kingdom in the past five years and drugs from abroad that are curr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neuro-Oncology
سال: 2018
ISSN: 1522-8517,1523-5866
DOI: 10.1093/neuonc/noy018